Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant PK/Safety in Chinese Healthy Women
NCT05381142Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in vasomotor symptoms and hot flashes comparing Elinzanetant with Placebo (2 arms). Primary endpoints: Maximum Observed Drug Concentration (Single Dose), Area Under the Curve (Single Dose) and 2 more. Started May 2022; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptomshot flashes
Beyond the preview
Go deeper on NCT05381142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381142.